Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
about
Pro-urokinase-type plasminogen activator is a substrate for hepsinThe pharmacological landscape and therapeutic potential of serine hydrolasesStructural insight into distinct mechanisms of protease inhibition by antibodiesStructure of an Fab–Protease Complex Reveals a Highly Specific Non-canonical Mechanism of InhibitionAllosteric antibody inhibition of human hepsin proteaseAssociation of hepsin gene variants with prostate cancer risk and prognosisProteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta.Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.An allosteric anti-hepsin antibody derived from a constrained phage display library.Emerging principles in protease-based drug discovery.Identification of hepsin and protein disulfide isomerase A3 as targets of gelatinolytic action in rat ovarian granulosa cells during the periovulatory periodCorin in clinical laboratory diagnosticsTargeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.Membrane-anchored serine proteases in health and disease.Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model.Type II transmembrane serine proteases as potential targets for cancer therapy.High Hepsin expression predicts poor prognosis in Gastric Cancer.Structural and mechanistic insight into how antibodies inhibit serine proteases.Recent advances in the application of antibodies as therapeutics.Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.The role of type II transmembrane serine protease-mediated signaling in cancer.HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.Effect of anthralin on cell viability in human prostate adenocarcinoma.Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition.Decreased expressions of hepsin in human hepatocellular carcinomas.SERPINB12 Is a Slow-Binding Inhibitor of Granzyme A and Hepsin.The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1).Molecular and physiological mechanisms of membrane receptor systems functioning.Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases.The serine proteinase hepsin is an activator of pro-matrix metalloproteinases: molecular mechanisms and implications for extracellular matrix turnover.Serine protease hepsin regulates hepatocyte size and hemodynamic retention of tumor cells by hepatocyte growth factor signaling in mice.Functional analysis of corin protein domains required for PCSK6-mediated activation.Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.Variants in the HEPSIN gene are associated with susceptibility to prostate cancer.
P2860
Q24299743-78C4CCB5-EABF-48E8-ACE3-23F5ACC4EF09Q26995817-BFA783D5-F0A5-41C6-AE44-E4113643C886Q27649305-09B418D2-4F8A-4215-BFB4-EC7E4246DEDCQ27650727-777F8E03-93B2-4C2A-B324-20F77A985784Q27675904-FEC3AA60-FF40-4B96-BF8D-7DBF09A0244BQ33872480-D365909B-41DD-4DB7-9CB6-4B49906C514CQ34074338-7C1834E0-BFDB-444B-BDB3-29FD5C805D93Q34078067-92264E0F-4B6C-469D-A652-84020C361DE7Q34132742-9994CBBF-08EB-44C7-BFED-E33A84082294Q34282102-1CB519BA-B66A-4BC3-BC76-C9D6F4C3946BQ35250001-55BB9F63-EE21-4147-8BAE-531D6EFFBCC3Q35634038-281B836F-CDB6-47E4-8017-7B38D8A32DD8Q36545204-C1D7BB49-3CA0-44D9-A641-C273F3714966Q36969010-2A60A299-BF1B-44AB-AA32-FD75995A72AAQ37122556-DD20389A-EFE0-4AD7-B972-4B6294281AF5Q37168351-E1FC73FA-3207-463D-BA99-9B59A11A33AEQ37411864-0E7BDF3F-4A39-47BF-AA68-E4F15B1B2DAFQ37779571-DE9C755F-E2B0-47F8-BD75-6806665C997DQ37968255-373F3BFF-3A0A-4C87-9459-878CC3227763Q38184632-09F6B7E8-AF5D-4DF9-A54D-1DE518717E8AQ39015415-820E349E-294D-40F1-93AA-9B9309560535Q39145828-5EA4FC03-025A-473D-826C-562997DF33A4Q39301892-6867ED87-8395-456D-B8CD-42F6175DC03EQ39326983-D23F076D-C6CC-49D8-8C04-ED11CE6A423EQ39941224-D8441E5D-ED57-440C-9B2B-43D80294BA3FQ40060517-0EE07F95-7AC1-4A3F-A5D0-1215989D0781Q40243509-F5435A07-320B-44C5-BC28-E4951E364C86Q42046520-7BC88024-3771-4E0A-9D91-F425CBA12722Q42080648-4B60C2B8-31F4-49CE-BD8B-9E4AD88017C2Q42153161-BCC121F2-35DA-48A5-B8E4-BA01FFBDE185Q47155746-0FE322EA-7C69-4B89-9573-E07DC61DB577Q47168535-792E74CB-A68D-4B0D-9160-A62F12EF88E4Q47315721-EE619B52-FCA3-472A-9616-51CF61BE5D8BQ47359170-3C7F9669-48C9-45FA-BAC0-C44B61B9A389Q52661781-257B0F90-CA5D-4185-8D83-0993DBF94CECQ55043279-46F992A7-CC68-4DA9-9427-91E37F6BB703Q55056216-B8EADC61-1599-4A39-9255-75E57F5DB8D9
P2860
Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Antibodies neutralizing hepsin ...... varian tumor cells in culture.
@en
type
label
Antibodies neutralizing hepsin ...... varian tumor cells in culture.
@en
prefLabel
Antibodies neutralizing hepsin ...... varian tumor cells in culture.
@en
P2093
P1433
P1476
Antibodies neutralizing hepsin ...... varian tumor cells in culture.
@en
P2093
Alicia Newton
Bob Mintzer
David Light
David Vogel
Doug Schneider
Gordon Parry
Harald Dinter
Jian-Ai Xuan
Marc Whitlow
Mark Polokoff
P304
P356
10.1158/0008-5472.CAN-05-2983
P407
P577
2006-04-01T00:00:00Z